Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 2

Incidence of Intraocular Pressure Elevation After Intravitreal Dexamethasone and Triamcinolone Acetonid Application for The Treatment of Persistent Diabetic Macular Edema

Dirençli Diyabetik Makula Ödemi Tedavisinde İntravitreal Deksametazon ve Triamsinolon Asetonid Uygulamaları Sonrası Göz İçi Basınç Artışı Görülme Sıklığının Değerlendirilmesi

Pages
147–152
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After low-dose IVTA injection and DEX implantation, the change in IOP levels were similar in the short term follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To compare the effect of short term intraocular pressure (IOP) change after low-dose intravitreal triamcinolone acetonid (IVTA) injection and sustained-release dexamethasone (DEX) implantation in cases with persistent diabetic macular edema (DME).Materials and Methods: In this study, 59 eyes of 59 patients, who received intravitreal corticosteroids due to persistent DME were analyzed retrospectively.
📊
Key Findings & Data:Group 1 was consisted of 27 eyes with IVTA injection (2 mg/0.05 ml) and group 2 had 32 eyes with DEX implantation (0.7 mg).
💡
Conclusion & Impact:After low-dose IVTA injection and DEX implantation, the change in IOP levels were similar in the short term follow-up.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To compare the effect of short term intraocular pressure (IOP) change after low-dose intravitreal triamcinolone acetonid (IVTA) injection and sustained-release dexamethasone (DEX) implantation in cases with persistent diabetic macular edema (DME).Materials and Methods: In this study, 59 eyes of 59 patients, who received intravitreal corticosteroids due to persistent DME were analyzed retrospectively. Group 1 was consisted of 27 eyes with IVTA injection (2 mg/0.05 ml) and group 2 had 32 eyes with DEX implantation (0.7 mg). IOP, best corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated before injection and at the 1st and 3rd months after injection. Results: The mean baseline, 1st and 3rd month IOP measurements were 14.6 ± 3.1, 16.1 ± 3.2 and 17.8 ± 4.8 mmHg in group 1, 15.1 ± 2.2, 17.6 ± 4.8 and 18.3 ± 4.2 mm Hg in group 2, respectively. Baseline, 1st and 3rd month IOP measurements were not signifi cantly different between groups (p>0.05). At the end of 3rd month follow-up, steroid induced ocular hypertension (OHT) was observed in 7 cases (%25) in group 1 and 9 cases (%30) in group 2. In each group, the improvement of BCVA and CMT from baseline were statistically signifi cant at the 1st and 3rd months follow-up (p=0.001 for each).Conclusions: Intravitreal corticosteroid injection was an effective treatment method in the treatment of persistent DME. After low-dose IVTA injection and DEX implantation, the change in IOP levels were similar in the short term follow-up.

Özet

Amaç: Dirençli diyabetik makula ödemi (DMÖ) olgularında düşük doz intravitreal triamsinolon asetonid (İVTA) enjeksiyonu ve yavaş alınımlı deksametazon (DEX) implantasyonunun kısa dönem göz içi basınç (GİB) değişimlerine etkisini karşılaştırmak.Gereç ve Yöntem: Bu çalışmada dirençli DMÖ nedeniyle intravitreal kortikosteroid uygulanan 57 hastanın 59 gözü retrospektif olarak incelendi. İVTA enjeksiyonu (2 mg/0.05 ml) yapılan 27 göz grup 1, DEX implantı (0.7 mg) yapılan 32 göz grup 2 olarak belirlendi. Hastaların enjeksiyon öncesi, enjeksiyon sonrası 1. ve 3. ay takiplerindeki GİB değerleri, en iyi düzeltilmiş görme keskinliği (EDGK) ve santral makula kalınlığı (SMK) ölçümleri değerlendirildi. Bulgular: Başlangıç, 1. ay ve 3. ay ortalama GİB ölçümleri grup 1'de sırasıyla 14.6±3.1, 16.14±3.2 ve 17.86±4.8 mmHg iken; grup 2'de 15.1±2.2, 17.68±4.8 ve 18.3±4.2 mmHg idi. Gruplar arasında başlangıç, 1. ay ve 3. ay GİB ölçümleri arasında anlamlı fark bulunmadı (p>0.05). Üç aylık takip sonucunda grup 1'de 7 (%25), grup 2'de 9 (%30) olguda steroide bağlı oküler hipertansiyon (OHT) gelişimi görüldü (p>0.05). Her iki grupta da başlangıca göre 1. ve 3. ay takiplerinde EDGK ve SMK ölçümlerinde istatistiksel anlamlı iyileşme saptandı (herbiri, p=0.001).Sonuç: Dirençli DMÖ tedavisinde intravitreal kortikosteroid enjeksiyonu etkili bir tedavi yöntemidir. Düşük doz İVTA enjeksiyonu ve yavaş salınımlı DEX implantı sonrası kısa dönemde benzer GİB artışı görülmektedir.

🔖

Cite This Article

ARIKAN, M. Y., MUTLU, M., TOKLU, Y., ÖZEN, U., KARS, M. E. (2017). Incidence of Intraocular Pressure Elevation After Intravitreal Dexamethasone and Triamcinolone Acetonid Application for The Treatment of Persistent Diabetic Macular Edema. Retina-Vitreus, Cilt: 26 - Sayı: 2, 147–152. https://ajindex.com/articles/304948

References (12)

  1. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1964-74
  2. Kaynak S. Diabetik makü ler ödem ve kanıta dayalı tedavi seçenekleri. Ret-Vit 2012;20:157-175 3. Brown DM, Nguyen QD, Marcus DM, et al. RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120:2013-22
  3. Boyer DS, Yoon YH, Belfort R Jr, et al. Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophtalmology 2014;121:1904-14
  4. Pravin U Dugel, Francesco Bandello, Anat Loewenstein.Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clin Ophthalmol 2015;9:1321-35
  5. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 2011;118:1580-87
  6. Ciulla TA, Harris A, McIntyre N, et al. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fl uocinolone acetonide implant. Expert Opin Pharmacother 2014;15:953-9
  7. Boyer DS, Faber D, Gupta S, et al. Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915- 23
  8. Zucchiatti I, Lattanzio R, Querques G, et al. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 2012;228:117-22
  9. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-9
  10. Diabetic Retinopathy Clinical Research Network, Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-51
  11. Armaly MF. Effect of corticosteroids on intraocular pressure and fl uid dynamics. I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963;70:482-91
  12. Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of resp